Get Pembrolizumab Head And Neck Cancer UK. Pembrolizumab for recurrent/metastatic head and neck cancer: Head and neck cancers comprise the sixth most common cancer type in the united states with estimated 14,620 deaths in 2019.
The most extensive data come from small series of patients.
Immunotherapy with pembrolizumab (keytruda, merck & co), either as monotherapy or in combination with chemotherapy, offers a new standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma (hnscc), say experts discussing the results from the. Immunotherapy drug pembrolizumab was given to 301 patients, 281 were treated with. Head and neck cancers comprise the sixth most common cancer type in the united states with estimated 14,620 deaths in 2019. Nivolumab and pembrolizumab release this brake, allowing the immune system to mount a stronger attack.